Please login to the form below

Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603

Alderley Park, UK, January 2020

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603 for the treatment of onychomycosis.

The IND is a crucial milestone in the continued development of BB2603, a nanoformulated, topical form of terbinafine for the treatment of onychomycosis (fungal toenail). With the IND in place the company has initiated a Phase IIb international, multicentre double-blinded study.

The primary outcome of this study is to look at the efficacy BB2603 in onychomycosis, with a secondary dose finding outcome also being investigated.

John Ridden, CEO said: “Having received clearance from the FDA we are looking forward to the opportunity to work with over 20 international sites on the Phase IIb trial of BB2603 with the first patient expected to be recruited in March 2020.This is a key milestone in our path to commercialisation of our nanotechnology product portfolio.”

With BB2603, Blueberry Therapeutics aim to maintain the efficacy of the oral gold standard treatment, but at a lower dose. Delivering the active pharmaceutical ingredient using nanotechnology ensures it penetrates across the nail plate and reaches the target site of action in a controlled manner, meaning lower doses can be used and systemic side effects are minimised.

ENDS

Blueberry Therapeutics Limited Media Contact

Elle Bell – Onyx Health

ebell@onyxhealth.com

Tel: +44 (0) 191 640 3638

Notes to Editors

About Blueberry Therapeutics Limited

Blueberry Therapeutics Ltd., incorporated in November 2011, is a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections.  The company is using its state-of-the-art nanotechnology to develop high value medicines where a reduced dose and improved drug delivery is needed, to overcome existing efficacy, tolerability and safety profile concerns.

Blueberry Therapeutics combines expert in-house resources with selected outsource partners and collaborators to take projects through from preclinical research onto de-risked human clinical proof of concept and then on to the market. For more information, please visit http://www.blueberrytherapeutics.com

3rd February 2020

Share

Tags

Company Details

Onyx Health Ltd

01916403638

Contact Website

Address:
Hoults Yard
Walker Road
Newcastle upon Tyne
Tyne and Wear
NE6 1AB
United Kingdom

Latest content on this profile

PulmoBioMed Wins National Life Science Competition
Newly launched Northumbria University spinout PulmoBioMed has been handpicked as the winners of Onyx Health's ThinkBig competition
Onyx Health Ltd
Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
Leading biotechnology company NovaBiotics Ltd have secured a major licensing deal for their fungal nail treatment
Onyx Health Ltd
Newcells Biotech secures over £5m for 3D tissue models
Newcells Biotech have received multi-million investment to develop their pioneering 3D tissue models
Onyx Health Ltd
Onyx Health Targets Digital Growth with New Executive Director
Healthcare marketing communications agency Onyx Health have appointed Trevor Pill as their new Executive Director
Onyx Health Ltd
Onyx Health Launch National Competition for Life Science SMEs
Healthcare marketing communications agency Onyx Health are launching a national competition #ThinkBig to help health and life sciences SMEs bounce back from the COVID-19 crisis
Onyx Health Ltd
Onyx Health Celebrates Its 10th Anniversary with Five New Hires
Onyx Health have marked their 10th anniversary by welcoming five new members to their rapidly expanding team. These appointments come on the back of the agency’s continued growth throughout the COVID-19 crisis
Onyx Health Ltd